Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyanide SCHEMBL22130180 | 0.90 | SCN9A (0.33) | — | |
| Cyanide SCHEMBL25405838 | 0.83 | DDB1 (0.38) | KDM4EMAPTNPSR1RXFP1 | |
| Cyanide SCHEMBL22130265 | 0.79 | KDM4E (0.36) | KDM4ERXFP1 | |
| Cyanide SCHEMBL22130070 | 0.77 | — | — | |
| Cyanide SCHEMBL25405741 | 0.75 | KDM4E (0.44) | KDM4EMAPTNPSR1RXFP1 | |
| Cyanide SCHEMBL22130058 | 0.75 | LMNA (0.45) | KDM4E | |
| Cyanide SCHEMBL25403775 | 0.73 | HPD (0.33) | KDM4ERXFP1 | |
| SCHEMBL30349705 | 0.73 | NPC1 (0.41) | CTSCKDM4EMAPTNPSR1 | |
| Cyanide SCHEMBL25406456 | 0.72 | HPD (0.46) | KDM4EMAPT | |
| Cyanide SCHEMBL22130079 | 0.72 | CNR2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295095-A1 | NOVEL FUSED-HETEROCYCLYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-09-21 | — | — | US | claimed |
| EP-4169905-A1 | NOVEL FUSED HETEROCYCLIC CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2023-04-26 | — | — | EP | claimed |
| US-20230295095-A1 | NOVEL FUSED-HETEROCYCLYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-09-21 | — | — | US | disclosed |
| EP-4169905-A1 | NOVEL FUSED HETEROCYCLIC CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2023-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295095-A1 | NOVEL FUSED-HETEROCYCLYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS AND USE THEREOF | CBR3, DBF4, DDT | CTSC 2219/4885KDM4E 2516/4885MAPT 3518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.